Comparative Pharmacology
Head-to-head clinical analysis: AKNE MYCIN versus ELASE CHLOROMYCETIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AKNE MYCIN versus ELASE CHLOROMYCETIN.
AKNE-MYCIN vs ELASE-CHLOROMYCETIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin, a macrolide antibiotic, binds to the 50S subunit of bacterial ribosomes and inhibits protein synthesis by blocking translocation of peptidyl-tRNA. Topically, it reduces Propionibacterium acnes colonization and exhibits anti-inflammatory properties.
Elase-Chloromycetin is a combination product containing fibrinolysin and desoxyribonuclease (Elase) for enzymatic debridement, and chloramphenicol (Chloromycetin), a bacteriostatic antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit.
Topical application of 2% solution twice daily to affected areas.
Topical application: Apply thin layer to affected area 2-3 times daily.
None Documented
None Documented
2-3 hours (normal renal function); up to 24-36 hours in severe renal impairment
Chloramphenicol has a terminal elimination half-life of 1.5 to 4.0 hours in adults with normal renal and hepatic function. In neonates, half-life can be prolonged to 24-48 hours, necessitating dose adjustment. Elase has no systemic half-life as it acts locally.
Primarily renal (60-80% unchanged); minor biliary/fecal (15-30%)
Chloramphenicol is primarily excreted renally (approximately 90% as inactive metabolites). Fecal excretion accounts for less than 1% of the dose. Biliary elimination is negligible. Elase (fibrinolysin and desoxyribonuclease) is locally degraded and not systemically absorbed, thus its excretion is irrelevant.
Category C
Category C
Topical Antibiotic
Topical Antibiotic and Debriding Agent